The House voted to delay an Affordable Care Act health insurance tax until 2021 and expand Health Savings Accounts; in a large clinical trial, an Alzheimer drug reduced plaques in the brains of patients and slowed the progression of dementia; after leaving high-profile positions in government and at healthcare organizations, more big names in healthcare are ending up at Google's companies instead of universities.
A health insurance tax under the Affordable Care Act (ACA) that Republicans and some Democrats criticized for causing premiums to increase could be delayed until 2021. The House passed a bill that would delay the tax, which was already suspended for 2019, for 2 more years, reported The Hill. The purpose of the tax is to help fund the ACA’s insurance expansion. The bill also included a measure to expand Health Savings Accounts and increase the number of ACA enrollees who can purchase catastrophic plans with high deductibles.
In a large clinical trial, a drug was shown to reduce plaques in the brains of patients, thus slowing the progression of dementia. According to The New York Times, this represents the first time an Alzheimer drug has successfully done both. The results were presented at the Alzheimer’s Association International Conference. The trial involved patients with mild cognitive impairment or mild Alzheimer dementia. Currently, there are only a few medications that slow memory decline for a few months. The drug still has to go onto a phase 3 trial, where other promising Alzheimer drugs have failed.
More big name healthcare officials and executives are taking jobs at Google’s companies instead of moving onto positions at universities. STAT highlighted how appointments of people like Toby Cosgrove, MD, the former president and CEO of Cleveland Clinic; Robert Califf, MD, former commissioner of the FDA; and Thomas Insel, MD, former director of the National Institute of Mental Health, show that Google’s companies are becoming important players in healthcare.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More